432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma

• Merrick Ross,
• Reinhard Dummer,
• Lev Demidov,
• Edward Chan,
• David Gyorki,
• Robert Conry,
• Hoi-Shen Radcliffe

Affiliations

Merrick Ross

Aff6 grid.240145.60000000122914776MD Anderson Cancer Center Houston TX USA

Reinhard Dummer

Department of Dermatology, University Hospital and University of Zurich, Zurich, Switzerland

Lev Demidov

10N. N. Blokhin Russian Cancer Research, Moscow, Russian Federation

Edward Chan

6Amgen Inc., Thousand Oaks, CA, USA

David Gyorki

2Peter MacCallum Cancer Centre, Melbourne, Australia

Robert Conry

5University of Alabama School of Medicine, Birmingham, AL, USA

Hoi-Shen Radcliffe

7Amgen Inc., Thousand Oaks, CA, USA